The global injection pen market is forecasted to expand at 7.0% CAGR to reach a market valuation of US$ 85.8 billion by the end of 2033, up from US$ 40.7 billion that was recorded for 2022.
Due to a rise in the incidence of needle sticks, there is a greater demand for injection pens over the conventional vial and needle procedure, which is encouraging the market to grow
Attribute | Details |
---|---|
Injection Pen Market Size (2023) | US$ 43.4 Billion |
Forecasted Market Value (2033) | US$ 85.8 Billion |
Value CAGR (2023 to 2033) | 7.0% |
Collective Value Share: Top 5 Countries (2022) | 53.1% |
Key Market Players | Novo Nordisk A/S, Medtronic plc, Becton, Dickinson and Company, Sanofi, Eli Lilly and Company, Merck, AstraZeneca, Hoffmann-La Roche Ltd., Owen Mumford Ltd, Ypsomed AG, Terumo Medical Corporation, Braun Medical, Sun Pharmaceutical Industries Ltd. |
Increasing numbers of chronic diseases, favorable reimbursement and government support, the growing number of regulatory approvals, and technological advancements in injectable pens are all driving factors in the market.
Injection pens are the ideal option as chronic conditions require frequent medication administration. Injection pens have replaced other delivery methods for injectable medications as the standard. Their popularity has increased as a result of their convenience and ability to be administered directly by the patient without a medical professional's assistance.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for injection pen expanded at a CAGR of 6.4% during the historic period (2017 to 2022) and reached a market value of US$ 40.7 billion in 2022.
Globally, diabetes is one of the main causes of death. As a result, the market for injection pen is being driven by the rising number of diabetic patients of all ages around the world as well as the ease of use and accuracy of insulin dose.
It is expected that future technological developments in injection pens will stimulate the market globally. Furthermore, technological developments like improved memory and precise dosage administration will contribute to a growth of the market. For instance, additional technical developments include Insul Check, a cap for insulin pens with a sensor to monitor pen usage temperature. The iSenz insulin pen adaptor has a capability that can scan an object and determine the amount of insulin present.
The pricing of the injection pens makes them more accessible to people of all ages and geographies. Most injectable pens fall into two categories, reusable injection pens or disposable injection pens. A large number of patients prefer using prefilled injectable pens, which are disposable pens, to administer medications because of their convenience.
Market Statistics | Details |
---|---|
Jan–Jun (H1), 2021 (A) | 5.36% |
Jul–Dec (H2), 2021 (A) | 7.39% |
Jan–Jun (H1),2022 Projected (P) | 5.04% |
Jan–Jun (H1),2022 Outlook (O) | 5.51% |
Jul–Dec (H2), 2022 Outlook (O) | 7.42% |
Jul–Dec (H2), 2022 Projected (P) | 6.71% |
Jan–Jun (H1), 2023 Projected (P) | 5.46% |
BPS Change : H1,2022 (O) - H1,2022 (P) | 47↑ |
BPS Change : H1,2022 (O) - H1,2021 (A) | 14↑ |
BPS Change: H2, 2022 (O) - H2, 2022 (P) | 71↑ |
BPS Change: H2, 2022 (O) - H2, 2021 (A) | 03↑ |
Inadequate training and guidance for the use of advanced delivery systems, like injectable pens, results in inappropriate use, exposing patients and healthcare personnel to danger. This might affect the use of injection pens in a hospital setting. Furthermore, injection pens might carry insulin with variable strength. This increases the risk of overdosing in case the dose strength is not measured. Reusing insulin pens is another problem.
Additionally, patients have been seen using normal syringes without taking off the inner needle cover. The FDA claims that insulin pen treatment has also been linked to hyperglycemia in some individuals because it is difficult to regulate the dosage.
Injection pens market is getting slowed down due to injury and needle stick concern. As a result, there are several needle-free devices with the additional advantage of not triggering needle phobia commercially available on the market, which is a significant barrier to the widespread use of injection pen.
The growing geriatric population worldwide is expected to create lucrative opportunities for the injection pen market throughout the projected timeframe. With ageing, the overall immunity gets deteriorated, resulting in number of health issues in an individuals including chronic disease such as cardio vascular diseases and diabetes.
The downsides of using conventional syringes are one of the main reasons why consumers are switching to advanced injection pens. The pharmaceutical industry's increasing investments in the development of new medications are driving up consumer demand, which is in turn driving up demand for injectable pens for effectively administering medications. The global injection pen market is expanding as a result of rising healthcare expenditure and increased public awareness of the availability of novel and convenient injection pens.
The injection pen market is expanding rapidly due to the increased prevalence of chronic diseases like cancer and autoimmune diseases. The International Agency for Research on Cancer stated that there were about more than 19.3 million cancer cases and 10 million cancer-related deaths worldwide in 2020.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Country | The United States |
---|---|
Market Share (2023) | 28.9% |
Market Share (2033) | 29.9% |
BPS Analysis | 96 |
Country | China |
---|---|
Market Share (2023) | 8.1% |
Market Share (2033) | 8.7% |
BPS Analysis | 61 |
Country | Germany |
---|---|
Market Share (2023) | 5.5% |
Market Share (2033) | 5.7% |
BPS Analysis | 16 |
Country | India |
---|---|
Market Share (2023) | 5.5% |
Market Share (2033) | 5.9% |
BPS Analysis | 43 |
Country | Japan |
---|---|
Market Share (2023) | 5.2% |
Market Share (2033) | 5.3% |
BPS Analysis | 9 |
The USA is expected to dominate the global market at around 28.9% by the end of 2023.
The growing incidence of non-communicable diseases in the USA, including diabetes, cancer, cardiovascular disease, and multiple sclerosis have uplifted the market. In 2020, according to the USA CDC, there were approximately 34.2 million USA citizens who had diabetes and over 88 million had pre-diabetes. The use of injectable pens has expanded as a result of the rising prevalence of diabetes in the general population.
Germany is set to hold a share of 5.5% of the global market in 2023.
The primary drivers of the growth of the German market for injection pens include rising healthcare spending, increased awareness of advanced medication delivery systems for conditions like diabetes, cardiovascular problems etc., and the easy availability of injection pens and their cartridges. In Germany, cardiovascular diseases (CVDs) remain the leading cause of death, accounting for 34.3% of all deaths in 2020, according to a study published in the journal The Burden of Cardiovascular Diseases in Germany.
China is expected to hold a market share at 8.1% of the global market at the end of 2023.
The rising prevalence of several chronic diseases in the population as a result of unhealthy dietary pattern, physical inactivity, and rising alcohol and tobacco consumption among the general populations are factors anticipated to drive the market. In China, the prevalence of chronic diseases in the country was 81.1%, which equates to 179.9 million affected Chinese older adults, according to a study that was published in the Journal of The American Medical Directors Association in 2022. The prevalence rose with age and peaked between the ages of 80 and 84.
Disposable injection pens are expected to hold a market share of 58.6% by the end of 2023.
Due to the affordability and safety of disposable injection pens, the disposable pen segment is predicted to drive the market over the forecast period. These injection pens enhance safety against blood-borne infections and can only be used once. The segment has been expanding over the past few years because to factors such ease of accessibility, rising consumer awareness, and an increase in the number of insulin related diseases.
Based on indication, diabetes is expected to hold a majority of the segment share at the end of 2023 at around 56.9%.
Blood glucose levels rise as a result of unhealthy diet habits. It is a significant factor in type 1 diabetes. Type 2 diabetes develops as a result of the body becoming resistant to insulin. The prevalence of type 1 and type 2 diabetes is increasing worldwide, which is boosting this segment's expansion. The International Diabetes Federation predicts that there will be around 643 million diabetics worldwide by 2030.
As per distribution channel, the hospital pharmacies segment is set to hold 35.5% revenue share in 2023.
The presence of vast patient pool of chronic diseases especially for cardiovascular diseases and diabetes seek treatment and care at hospitals, ultimately leading to product sales from hospital pharmacies under the guidance of medical experts and professionals.
The injection pen market is competitive and has several established companies. To increase their position in the market, key players have been adopting methods such as product launches and certification/ product approvals for new product.
Recent Market Developments
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the injection pen market, which are available in the full report.
Attribute | Details |
---|---|
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2017 to 2022 |
Market Analysis | US$ Million for Value |
Key Regions Covered | North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa |
Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, United KLingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
Key Market Segments Covered | Product, indication, distribution channel and region |
Key Companies Profiled |
|
Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
Pricing | Available upon Request |
The market is valued at US$ 43.4 million in 2023.
Medtronic plc, & Becton, Dickinson, and Company are the leading market players.
The market is expected to value at US$ 85.8 billion in 2033.
The disposable segment is likely to remain preferred through 2033.
The market registered a CAGR of 6.4% from 2017 to 2022.
1. Executive Summary | Injection Pen Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Technology Roadmaps 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Product Adoption Rate – Key Statistics 4.2. Disease Epidemiology 4.3. Regulatory Scenario 4.4. Product USP Analysis 4.5. PESTEL Analysis 4.6. Porter’s Analysis 4.7. Value Chain Analysis 4.8. Promotional Strategies, By Key Players 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Outlook 5.1.3. Global Injectable Drug Delivery Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Prevalence of Chronic Diseases 5.2.2. Increasing Needle Sticks 5.2.3. Shifting Preference toward 5.2.4. Growing Geriatric Population 5.2.5. Mergers and Acquisitions 5.2.6. Technological Developments 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Product 6.1.2. By Indication 6.1.3. By Distribution Channel 6.1.4. By Region 6.2. 2022 Market Scenario 7. Global Market Demand (in Value US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 7.2. Current and Future Market Value (US$ Million) Analysis and Forecast, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis, by Product, 2017 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Product, 2023 to 2033 8.3.1. Disposables 8.3.2. Reusables 8.4. Market Attractiveness Analysis, by Product 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis, By Indication, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Indication, 2023 to 2033 9.3.1. Anaphylaxis 9.3.2. Diabetes 9.3.3. Cardiovascular Diseases 9.3.4. Multiple Sclerosis 9.3.5. Rheumatoid Arthritis 9.3.6. Cancer 9.3.7. Others 9.4. Market Attractiveness Analysis, by Indication 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Distribution Channel, 2023 to 2033 10.3.1. Hospital Pharmacies 10.3.2. Drug Stores 10.3.3. Retail Pharmacies 10.3.4. Online Pharmacies 10.4. Market Attractiveness Analysis, by Distribution Channel 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis, by Region, 2017 to 2022 11.3. Current and Future Market Value (US$ Million) Analysis and Forecast, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis, by Region 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis, by Market Taxonomy, 2017 to 2022 12.3. Current and Future Market Value (US$ Million) Analysis and Forecast, 2023 to 2033 12.3.1. By Country 12.3.1.1. USA 12.3.1.2. Canada 12.3.2. By Product 12.3.3. By Indication 12.3.4. By Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Product 12.4.3. By Indication 12.4.4. By Distribution Channel 12.5. Market Trends 12.6. Drivers and Restraints - Impact Analysis 12.7. Country Level Analysis & Forecast 12.7.1. USA Market Analysis 12.7.1.1. Introduction 12.7.1.2. Market Analysis and Forecast, by Market Taxonomy 12.7.1.2.1. By Product 12.7.1.2.2. By Indication 12.7.1.2.3. By Distribution Channel 12.7.2. Canada Market Analysis 12.7.2.1. Introduction 12.7.2.2. Market Analysis and Forecast, by Market Taxonomy 12.7.2.2.1. By Product 12.7.2.2.2. By Indication 12.7.2.2.3. By Distribution Channel 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis, by Market Taxonomy, 2017 to 2022 13.3. Current and Future Market Value (US$ Million) Analysis and Forecast, 2023 to 2033 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Product 13.3.3. By Indication 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Product 13.4.3. By Indication 13.4.4. By Distribution Channel 13.5. Market Trends 13.6. Drivers and Restraints - Impact Analysis 13.7. Country Level Analysis & Forecast 13.7.1. Mexico Market Analysis 13.7.1.1. Introduction 13.7.1.2. Market Analysis and Forecast, by Market Taxonomy 13.7.1.2.1. By Product 13.7.1.2.2. By Indication 13.7.1.2.3. By Distribution Channel 13.7.2. Brazil Market Analysis 13.7.2.1. Introduction 13.7.2.2. Market Analysis and Forecast, by Market Taxonomy 13.7.2.2.1. By Product 13.7.2.2.2. By Indication 13.7.2.2.3. By Distribution Channel 13.7.3. Argentina Market Analysis 13.7.3.1. Introduction 13.7.3.2. Market Analysis and Forecast, by Market Taxonomy 13.7.3.2.1. By Product 13.7.3.2.2. By Indication 13.7.3.2.3. By Distribution Channel 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis, by Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Value (US$ Million) Analysis and Forecast, 2023 to 2033 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. United Kingdom 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Product 14.3.3. By Indication 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Product 14.4.3. By Indication 14.4.4. By Distribution Channel 14.5. Market Trends 14.6. Drivers and Restraints - Impact Analysis 14.7. Country Level Analysis & Forecast 14.7.1. Germany Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast, by Market Taxonomy 14.7.1.2.1. By Product 14.7.1.2.2. By Indication 14.7.1.2.3. By Distribution Channel 14.7.2. Italy Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast, by Market Taxonomy 14.7.2.2.1. By Product 14.7.2.2.2. By Indication 14.7.2.2.3. By Distribution Channel 14.7.3. France Market Analysis 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast, by Market Taxonomy 14.7.3.2.1. By Product 14.7.3.2.2. By Indication 14.7.3.2.3. By Distribution Channel 14.7.4. United Kingdom Market Analysis 14.7.4.1. Introduction 14.7.4.2. Market Analysis and Forecast, by Market Taxonomy 14.7.4.2.1. By Product 14.7.4.2.2. By Indication 14.7.4.2.3. By Distribution Channel 14.7.5. Spain Market Analysis 14.7.5.1. Introduction 14.7.5.2. Market Analysis and Forecast, by Market Taxonomy 14.7.5.2.1. By Product 14.7.5.2.2. By Indication 14.7.5.2.3. By Distribution Channel 14.7.6. BENELUX Market Analysis 14.7.6.1. Introduction 14.7.6.2. Market Analysis and Forecast, by Market Taxonomy 14.7.6.2.1. By Product 14.7.6.2.2. By Indication 14.7.6.2.3. By Distribution Channel 14.7.7. Russia Market Analysis 14.7.7.1. Introduction 14.7.7.2. Market Analysis and Forecast, by Market Taxonomy 14.7.7.2.1. By Product 14.7.7.2.2. By Indication 14.7.7.2.3. By Distribution Channel 15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis, by Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Value (US$ Million) Analysis and Forecast, 2023 to 2033 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Product 15.3.3. By Indication 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Product 15.4.2. By Indication 15.4.3. By Distribution Channel 15.5. Market Trends 15.6. Drivers and Restraints - Impact Analysis 15.7. Country Level Analysis & Forecast 15.7.1. China Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast, by Market Taxonomy 15.7.1.2.1. By Product 15.7.1.2.2. By Indication 15.7.1.2.3. By Distribution Channel 15.7.2. Japan Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast, by Market Taxonomy 15.7.2.2.1. By Product 15.7.2.2.2. By Indication 15.7.2.2.3. By Distribution Channel 15.7.3. South Korea Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast, by Market Taxonomy 15.7.3.2.1. By Product 15.7.3.2.2. By Indication 15.7.3.2.3. By Distribution Channel 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis, by Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Value (US$ Million) Analysis and Forecast, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Indonesia 16.3.1.3. Malaysia 16.3.1.4. Thailand 16.3.1.5. Rest of South Asia 16.3.2. By Product 16.3.3. By Indication 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product 16.4.3. By Indication 16.4.4. By Distribution Channel 16.5. Market Trends 16.6. Drivers and Restraints - Impact Analysis 16.7. Country Level Analysis & Forecast 16.7.1. India Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast, by Market Taxonomy 16.7.1.2.1. By Product 16.7.1.2.2. By Indication 16.7.1.2.3. By Distribution Channel 16.7.2. Indonesia Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast, by Market Taxonomy 16.7.2.2.1. By Product 16.7.2.2.2. By Indication 16.7.2.2.3. By Distribution Channel 16.7.3. Malaysia Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast, by Market Taxonomy 16.7.3.2.1. By Product 16.7.3.2.2. By Indication 16.7.3.2.3. By Distribution Channel 16.7.4. Thailand Market Analysis 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast, by Market Taxonomy 16.7.4.2.1. By Product 16.7.4.2.2. By Indication 16.7.4.2.3. By Distribution Channel 17. Oceania Market 2012 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis, by Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Value (US$ Million) Analysis and Forecast, 2023 to 2033 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Product 17.3.3. By Indication 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product 17.4.3. By Indication 17.4.4. By Distribution Channel 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 17.7. Country Level Analysis & Forecast 17.7.1. Australia Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast, by Market Taxonomy 17.7.1.2.1. By Product 17.7.1.2.2. By Indication 17.7.1.2.3. By Distribution Channel 17.7.2. New Zealand Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast, by Market Taxonomy 17.7.2.2.1. By Product 17.7.2.2.2. By Indication 17.7.2.2.3. By Distribution Channel 18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis, by Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Value (US$ Million) Analysis and Forecast, 2023 to 2033 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Türkiye 18.3.1.3. South Africa 18.3.1.4. North Africa 18.3.1.5. Rest of Middle East and Africa 18.3.2. By Product 18.3.3. By Indication 18.3.4. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Product 18.4.2. By Indication 18.4.3. By Distribution Channel 18.5. Market Trends 18.6. Drivers and Restraints - Impact Analysis 18.7. Country Level Analysis & Forecast 18.7.1. GCC Countries Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast, by Market Taxonomy 18.7.1.2.1. By Product 18.7.1.2.2. By Indication 18.7.1.2.3. By Distribution Channel 18.7.2. Türkiye Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast, by Market Taxonomy 18.7.2.2.1. By Product 18.7.2.2.2. By Indication 18.7.2.2.3. By Distribution Channel 18.7.3. South Africa Market Analysis 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast, by Market Taxonomy 18.7.3.2.1. By Product 18.7.3.2.2. By Indication 18.7.3.2.3. By Distribution Channel 18.7.4. North Africa Market Analysis 18.7.4.1. Introduction 18.7.4.2. Market Analysis and Forecast, by Market Taxonomy 18.7.4.2.1. By Product 18.7.4.2.2. By Indication 18.7.4.2.3. By Distribution Channel 19. Market Structure Analysis 19.1. Market Analysis, by Tier of Companies 19.2. Market Share Analysis of Top Players 19.3. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Medtronic plc. 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Sales Footprint 20.3.1.4. Key Financials 20.3.1.5. SWOT Analysis 20.3.1.6. Strategy Overview 20.3.1.6.1. Marketing Strategy 20.3.1.6.2. Product Strategy 20.3.1.6.3. Channel Strategy 20.3.2. Novo Nordisk A/S 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Sales Footprint 20.3.2.4. Key Financials 20.3.2.5. SWOT Analysis 20.3.2.6. Strategy Overview 20.3.2.6.1. Marketing Strategy 20.3.2.6.2. Product Strategy 20.3.2.6.3. Channel Strategy 20.3.3. Medtronic plc 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Sales Footprint 20.3.3.4. Key Financials 20.3.3.5. SWOT Analysis 20.3.3.6. Strategy Overview 20.3.3.6.1. Marketing Strategy 20.3.3.6.2. Product Strategy 20.3.3.6.3. Channel Strategy 20.3.4. Becton, Dickinson and Company 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Sales Footprint 20.3.4.4. Key Financials 20.3.4.5. SWOT Analysis 20.3.4.6. Strategy Overview 20.3.4.6.1. Marketing Strategy 20.3.4.6.2. Product Strategy 20.3.4.6.3. Channel Strategy 20.3.5. Sanofi 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Sales Footprint 20.3.5.4. Key Financials 20.3.5.5. SWOT Analysis 20.3.5.6. Strategy Overview 20.3.5.6.1. Marketing Strategy 20.3.5.6.2. Product Strategy 20.3.5.6.3. Channel Strategy 20.3.6. Eli Lilly and Company 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Sales Footprint 20.3.6.4. Key Financials 20.3.6.5. SWOT Analysis 20.3.6.6. Strategy Overview 20.3.6.6.1. Marketing Strategy 20.3.6.6.2. Product Strategy 20.3.6.6.3. Channel Strategy 20.3.7. Merck 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Sales Footprint 20.3.7.4. Key Financials 20.3.7.5. SWOT Analysis 20.3.7.6. Strategy Overview 20.3.7.6.1. Marketing Strategy 20.3.7.6.2. Product Strategy 20.3.7.6.3. Channel Strategy 20.3.8. AstraZeneca 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Sales Footprint 20.3.8.4. Key Financials 20.3.8.5. SWOT Analysis 20.3.8.6. Strategy Overview 20.3.8.6.1. Marketing Strategy 20.3.8.6.2. Product Strategy 20.3.8.6.3. Channel Strategy 20.3.9. Hoffmann-La Roche Ltd. 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Sales Footprint 20.3.9.4. Key Financials 20.3.9.5. SWOT Analysis 20.3.9.6. Strategy Overview 20.3.9.6.1. Marketing Strategy 20.3.9.6.2. Product Strategy 20.3.9.6.3. Channel Strategy 20.3.10. Owen Mumford Ltd 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Sales Footprint 20.3.10.4. Key Financials 20.3.10.5. SWOT Analysis 20.3.10.6. Strategy Overview 20.3.10.6.1. Marketing Strategy 20.3.10.6.2. Product Strategy 20.3.10.6.3. Channel Strategy 20.3.11. Ypsomed AG 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Sales Footprint 20.3.11.4. Key Financials 20.3.11.5. SWOT Analysis 20.3.11.6. Strategy Overview 20.3.11.6.1. Marketing Strategy 20.3.11.6.2. Product Strategy 20.3.11.6.3. Channel Strategy 20.3.12. Terumo Medical Corporation 20.3.12.1. Overview 20.3.12.2. Product Portfolio 20.3.12.3. Sales Footprint 20.3.12.4. Key Financials 20.3.12.5. SWOT Analysis 20.3.12.6. Strategy Overview 20.3.12.6.1. Marketing Strategy 20.3.12.6.2. Product Strategy 20.3.12.6.3. Channel Strategy 20.3.13. Braun Medical 20.3.13.1. Overview 20.3.13.2. Product Portfolio 20.3.13.3. Sales Footprint 20.3.13.4. Key Financials 20.3.13.5. SWOT Analysis 20.3.13.6. Strategy Overview 20.3.13.6.1. Marketing Strategy 20.3.13.6.2. Product Strategy 20.3.13.6.3. Channel Strategy 20.3.14. Sun Pharmaceutical Industries Ltd. 20.3.14.1. Overview 20.3.14.2. Product Portfolio 20.3.14.3. Sales Footprint 20.3.14.4. Key Financials 20.3.14.5. SWOT Analysis 20.3.14.6. Strategy Overview 20.3.14.6.1. Marketing Strategy 20.3.14.6.2. Product Strategy 20.3.14.6.3. Channel Strategy 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports